[Respiratory syncytial virus infection in high-risk infants].
The authors describes the frequency of respiratory syncytial virus (RSV) infections in high risk infants in ten hospitals, between 01.02.1999.-15.03.1999. RSV antigen test were performed from the nasopharyngeal or throat swabs of 58 infants with respiratory tract infections. Thirteen patients were positive. Among them 11 were prematures. Six infants were still receiving treatment in Neonatal Intensive Care Unit, while seven infants were readmitted to a Pediatric Intensive Care Unit. Distribution of risk factors (prematurity, bronchopulmonary dysplasia, ventilation in newborn period, smoking in the family, unseparated brothers or sisters) in patients were comparable with the data of literature. Eight infants needed head box O2-therapy. No deaths were detected. The results of this preliminary study in Hungary might emphasize the importance of RSV infection, as a frequent cause of rehospitalization and the possibility of prevention (immunoglobulin, palivizumab).
Adamovich
K
K
Pécsi Tudományegyetem, Altalános Orvostudományi Kar, Gyermekklinika.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology* / Q000821:virology; D006801:Humans; D006814:Hungary / Q000453:epidemiology; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D007234:Infant, Premature; D000069455:Palivizumab; D012121:Respiration, Artificial / Q000009:adverse effects*; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000209:etiology; D012306:Risk; D012307:Risk Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab